BACE1 and early-onset autosomal dominant Alzheimer disease: Chopra N. et al. identified hsa-miR-298 as a potential therapeutic agent for Alzheimer’s disease, because of its capability to negatively regulate the expression of human amyloid-β precursor protein (APP), β-site APP-converting enzyme 1 (BACE1) and specific tau protein isoforms [74].